Intercept Pharma (ICPT) Tops Q1 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Intercept Pharmaceuticals (ICPT) PT Lowered to $16 at Stifel
May 6, 2021 12:27 PM EDTStifel analyst Derek C. Archila lowered the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $16.00 (from $29.00) while maintaining a Hold rating.
The analyst commented, "We are reiterating our Hold rating after ICPT reported 1Q21 financials and provided a business... More
